AtaiBeckley ATAI
NASDAQ ATAI
$7.36 +0.02 (+0.27%)
As of: Sep 4, 2026 · 2:41 PM EDT

AtaiBeckley (ATAI) Income towards Parent Company (2020 - 2026)

AtaiBeckley (ATAI) posted Income towards Parent Company of -$61.1 million for Q3 2025, down 120.04% sequentially from -$27.8 million in Q2 2025, and down 129.03% YoY from $210.3 million in Q3 2024.

Analysis

AtaiBeckley (ATAI) Income towards Parent Company (2020 - 2026) Analysis & Trends

AtaiBeckley's Income towards Parent Company history runs 2 years deep, the most recent figure standing at -$29.8 million for Q1 2026.

  • In Q1 2026, Income towards Parent Company fell 12.61% year-over-year to -$29.8 million; the TTM figure through Mar 2026 stood at -$56.3 million (changed N/A YoY), while the FY2025 annual figure was -$659.9 million, down 344.64% from the prior year.
  • Income towards Parent Company eased to -$61.1 million in Q3 2025 per ATAI's latest filing, from -$27.8 million in the prior quarter.
  • The five-year high for Income towards Parent Company was -$26.5 million in Q1 2025, with the low at -$29.8 million in Q1 2026.
  • A 5-year average of -$30.4 million and a median of -$31.8 million in 2023 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2021 and 2023: Income towards Parent Company plunged 842.61% in 2021, then soared 231.22% in 2023.
  • Over 5 years, Income towards Parent Company stood at -$49.3 million in 2021, then increased by 18.3% to -$40.3 million in 2022, then soared by 53.45% to -$18.7 million in 2023, then plunged by 107.97% to -$39.0 million in 2024, then plunged by 56.62% to -$61.1 million in 2025.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$61.1 million, -$27.8 million, and -$26.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.74 Bn 130.89 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.52 Bn 77.52 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.04 Bn 52.91 Bn 52.00 Mn
5 Revolution Medicines 44.06 Bn 44.06 Bn -
6 BeOne Medicines 39.98 Bn 34.88 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.46 Bn 32.15 Bn 992.69 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn -
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn
10 AtaiBeckley 1.60 Bn 1.60 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -32.58 Mn
Mar 31, 2026 -29.98 Mn
Sep 30, 2025 -61.10 Mn
Jun 30, 2025 -27.75 Mn
Jun 30, 2025 -27.75 Mn
Mar 31, 2025 -26.47 Mn
Mar 31, 2025 -26.51 Mn
Dec 31, 2024 -38.63 Mn
Sep 30, 2024 -26.66 Mn
Jun 30, 2024 -57.18 Mn
Mar 31, 2024 -25.68 Mn
Dec 31, 2023 -18.74 Mn
Sep 30, 2023 43.61 Mn
Jun 30, 2023 -31.86 Mn
Mar 31, 2023 -33.36 Mn
Dec 31, 2022 -45.32 Mn
Sep 30, 2022 -33.27 Mn
Jun 30, 2022 -30.86 Mn
Mar 31, 2022 -31.96 Mn
Dec 31, 2021 -52.14 Mn